Objective: The phase III GO-FORWARD study examined the efficacy and safety of golimumab
in patients with active rheumatoid arthritis (RA) despite methotrexate therapy. Methods: …

Background Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat rheumatoid
arthritis, but whether use of a different TNFα inhibitor can improve patient response is …

Background: Tumor necrosis factor-α is present in arteries in giant cell arteritis. Objective: To
evaluate the efficacy of infliximab, an anti–tumor necrosis factor-α agent, in giant cell arteritis…

Collagenase-3 (MMP13), a member of the matrix metalloproteinase (MMP) family of neutral
endopeptidases, is expressed in the skeleton during embryonic development and is highly …

Objective To evaluate the association of glucocorticoids and other purported risk factors
with the development of tuberculosis. Methods We conducted a case‐control study of …

Objective To assess the safety and efficacy of golimumab in methotrexate (MTX)–naive
patients with active rheumatoid arthritis (RA). Methods MTX‐naive patients with RA (n = 637) …

Objective To assess the risk of serious infections following 22 weeks of infliximab therapy,
and to further characterize the safety profile of infliximab in combination with background …

Objective To assess the efficacy, safety, and pharmacology of subcutaneous administration
of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with …

Objective To assess the efficacy of etanercept in the treatment of early active nonsteroidal
antiinflammatory drug (NSAID)–refractory nonradiographic axial spondyloarthritis (SpA). …

Objective Golimumab, administered subcutaneously every 4 weeks, has been shown to be
effective in reducing the signs and symptoms of active psoriatic arthritis (PsA) through week …